Characterization of Anti-Canine PD-1 Antibodies
Cells · 23.05.2026 · 15 (11) · 966
DOI: 10.3390/cells15110966 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 23.05.2026. Verfasst von Colin J Hartman und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, 621 Rubin Building-HB7936, 1 Medical Center Drive, Lebanon, NH 037…. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, GLF funding, NCI Cancer Center.
Abstract (Originalsprache)
Cancer is a leading cause of death in dogs, and incidence rates in dogs exceed those in humans. Current therapeutic options for canine cancer patients remain limited, with most treatments focused on palliative care. Immune checkpoint inhibitors such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies that have transformed cancer therapy and expanded the therapeutic options in humans could offer the same clinical benefit in canine cancer patients. This study details the engineering and functional characterization of mouse and chimeric mouse–canine anti-canine PD-1 (cPD-1) monoclonal antibodies. We demonstrate that anti-cPD-1 antibodies block the interaction between cPD-1 and its ligand cPD-L1, thereby inhibiting this immune signaling pathway. In a proof-of-concept study in seven companion canine cancer patients, intratumoral therapy with the lead anti-cPD-1 antibody (HugPetmab) was safe, well-tolerated, had no observed adverse events, and showed evidence of tumor control in a subset of injected tumors. These findings support the potential of HugPetmab antibody as an immunotherapeutic option for treating canine cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, 621 Rubin Building-HB7936, 1 Medical Center Drive, Lebanon, NH 03756, USA.
- Clinic for Radiation Oncology and Medical Oncology, University Animal Hospital, Vetsuisse Faculty, University of Zurich, 8057 Zurich, Switzerland.
- Institute of Laboratory Animal Science, University of Zurich, 8952 Schlieren, Switzerland.
- Villareal Garza, Hospital Veterinario, Monterrey 64390, Mexico.
- DIAGSA, Diagnóstico de Salud Animal, Naucalpan 53910, Mexico.
- VETCONNECT Diagnóstico por Imagen, Monterrey 64780, Mexico.
ORCID-Profile: Juan Carlos Pinto-Cárdenas, Anna M Schmoker, Johannes Vom Berg, Xiaoxuan Ge, Jay L Rothstein, Margaret E Ackerman, Steven Fiering, Hugo Arias-Pulido
Förderung
- NIH HHS
- GLF funding
- NCI Cancer Center
Zitieren
APA
Hartman, C. J., Sergent, P., Zimmermann, A. B. E., Chávez-Alexander-Anderson, O. R., Perez Alonso, L. A., Lines, L., Pinto-Cárdenas, J. C., Luna Dávalos, D., Schmoker, A. M., Palisoul, S. M., Vom Berg, J., Ge, X., Rothstein, J. L., Ackerman, M. E., Fiering, S., Noelle, R. J., & Arias-Pulido, H. (2026). Characterization of Anti-Canine PD-1 Antibodies. Cells, 15(11), 966. https://doi.org/10.3390/cells15110966
Vancouver
Hartman CJ, Sergent P, Zimmermann ABE, Chávez-Alexander-Anderson OR, Perez Alonso LA, Lines L, et al. Characterization of Anti-Canine PD-1 Antibodies. Cells. 2026;15(11):966. doi:10.3390/cells15110966
BibTeX
@article{Hartman2026,
author = {Hartman, Colin J and Sergent, Petra and Zimmermann, Anna Barbara Emilia and Chávez-Alexander-Anderson, Olga R and Perez Alonso, Luis A and Lines, Louise and Pinto-Cárdenas, Juan Carlos and Luna Dávalos, Daniel and Schmoker, Anna M and Palisoul, Scott M and Vom Berg, Johannes and Ge, Xiaoxuan and Rothstein, Jay L and Ackerman, Margaret E and Fiering, Steven and Noelle, Randolph J and Arias-Pulido, Hugo},
title = {Characterization of Anti-Canine PD-1 Antibodies},
journal = {Cells},
year = {2026},
volume = {15},
number = {11},
pages = {966},
doi = {10.3390/cells15110966}
}
EUVIMED